Nordic Bioscience receives Letter of Support from the U.S. Food and Drug Administration (FDA) for further study of the PRO-C3 biomarker assay in tumor fibrosis studies Paves way for further testing of the PRO-C3 biomarker assay, which identifies patients with hard to treat ‘fibrotic’ tumors, in further clinical trials US FDA recognizes need for a […]
Calliditas is one of European biopharma’s big success stories, bringing a rare disease drug to market and commercializing it using its own sales force. Richard Staines from Optimum Strategic Communications spoke with CEO Renée Aguiar-Lucander who outlined the challenges the company has faced on its journey. Lengthy experience as a life science investor has helped […]
Scarlet Therapeutics, a leader in red blood cell-based therapeutics (tRBCs), has launched with seed funding from Science Creates Ventures and Meltwind to further develop its platform. Born out of more than a decade of research at the University of Bristol and spearheaded by Professors Ashley Toye and Jan Frayne, with CEO Alistair Irvine at the […]
Over 30 years ago, the International Day of Action for Women’s Health was established by women’s rights activists to speak out and raise awareness of reproductive, sexual and maternal health issues faced by women globally. Today, the awareness day is still observed and aims to strive towards a holistic, women-centric and rights-based approach to […]
In episode four of Optimum Perspectives Podcast, our in-house IR expert, ex-Fund Manager Eva Haas interviewed Dan Mahony, Chairman of the BioIndustry Association (BIA), following his appointment as UK Life Sciences Investment Envoy to hear his plans for championing the UK’s Life Sciences industry. Dan’s circuitous and unplanned journey to his current role involved among […]
